APPLICATION
ANDA064217
TYPE
ANDA
ORIGINAL APPROVAL
1999-10-29
LATEST ACTION
2025-05-06
ROUTE
INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription
Products
RIFAMPINPrescription
RIFAMPIN 600MG/VIAL · INJECTABLE · INJECTION
Approval history
2025-05-06Labeling · Supplement 18 · standardAP
2025-05-06Labeling · Supplement 17 · standardAP
2011-06-13Labeling · Supplement 10AP
2001-01-29Labeling · Supplement 2AP
2000-09-29Labeling · Supplement 1AP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.